Inhaled caspofungin for severe Pneumocystis pneumonia
Part of Infections, Lungs & breathing clinical trials.
This trial tests an inhaled version of the drug caspofungin as an add-on treatment for people with severe Pneumocystis pneumonia. It aims to see if breathing in the drug can help fight the infection better than the standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a confirmed diagnosis of Pneumocystis pneumonia (a type of lung infection).
- You are currently on oxygen or a breathing machine to help you breathe.
- You have started the standard treatment (co-trimoxazole or a similar drug) within the last 2 days.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You are not allergic to echinocandin drugs (like caspofungin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
This trial tests different antibiotics for people with pneumocystis pneumonia who cannot take the standard treatment. It aims to find the best alternative therapy.
This trial is testing whether a shorter or longer course of steroids works better for people recovering from severe Pneumocystis pneumonia (a lung infection). If you are 18 or older and have been on steroids for about 10 days but no longer need extra oxygen, you may be able to join.
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This trial tests a new way to diagnose pneumocystis, a lung infection that can affect people with weakened immune systems. It may help find the infection faster and more accurately using samples taken from your lungs.
Hear when a new Pneumocystis Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.